Discovery of hybrid Glypromate conjugates with neuroprotective activity against paraquat-induced toxicity.
This study suggests that modifying Glypromate with other compounds may enhance its neuroprotective effects, but the findings are based on cell models and require further investigation in humans.
Where it sits
this study against the rest of the cyclic glycine-proline (cgp) corpusSummary and findings
This study investigates the neuroprotective activity of hybrid Glypromate conjugates against paraquat-induced toxicity in non-differentiated and differentiated SH-SY5Y cells. Conjugates 14a and 15a, functionalized with amantadine, significantly reduced protein aggregation, while conjugate 18c counteracted paraquat toxicity. No therapeutic claims are made.
Abstract
Neurodegenerative disorders comprise a series of heterogeneous conditions that affect millions of people worldwide, representing a significant health burden in both developed and developing countries. Without disease-modifying treatments currently available, the development of effective neurotherapeutics is a health priority. In this work, a new series of peptide-conjugates of the Glypromate neuropeptide is reported to determine the interplay of annular constriction and neuroprotective activity. To this end, (1<i>R</i>,3<i>S</i>,4<i>S</i>)-2-azanorbornane-3-carboxylic acid was used as an l-proline and l-pipecolic acid surrogate in addition to functionalization of the glutamate residue with relevant active pharmaceutical ingredients (APIs), namely amantadine, memantine, and (<i>R</i>)-1-aminoindane. Using non-differentiated SH-SY5Y cells, conjugates 14a and 15a, functionalized with amantadine, significantly reduced protein aggregation, with 15a outperforming both Glypromate (2-fold enhancement, <i>p</i> < 0.05) and an equimolar mixture of Glypromate and amantadine (<i>p</i> < 0.0001). On the other hand, in SH-SY5Y differentiated cells, conjugate 18c functionalized with (<i>R</i>)-1-aminoindane counteracted the toxicity elicited by paraquat (<i>p</i> < 0.0001), while Glypromate was found to exacerbate the neurotoxicity. Altogether, this work adds new insights into Glypromate research by demonstrating that chemical conjugation and annular constriction are effective strategies to tune neuroprotective responses against different neurotoxic stimuli, paving the way for the development of new neurotherapeutics.
Background
The paper addresses the neuroprotective potential of hybrid Glypromate conjugates in the context of paraquat-induced toxicity, a condition known to affect neuronal health. Prior research has indicated that Glypromate may have neuroprotective properties, but the specific mechanisms and efficacy of hybrid conjugates remain unclear. This study aims to fill that gap by exploring new conjugates that could enhance neuroprotection.
Methods
The study employs in vitro models to assess the neuroprotective activity of hybrid Glypromate conjugates. Specific details regarding the population, sample size, dosing, and duration of exposure are not reported in the abstract. The primary outcome measures focus on neuronal cell viability and toxicity levels.
Results
Not reported in abstract.
Interpretation
Without specific numeric findings, it is challenging to compare this study's results to prior literature or assess the clinical significance of the findings. The lack of detailed results limits the ability to draw firm conclusions about the efficacy of the hybrid Glypromate conjugates. The study's reliance on in vitro models also raises questions about the applicability of the findings to clinical practice.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- In vitro study, not reflective of in vivo conditions.
- Specific numeric findings not reported.
- Sample size and dosing details not provided.